Barton A

Eyre S

Hyrich K

Isaacs JD

Morgan AW

Plant D

Smith SL

Wilson AG

English

\ua9 The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. Objective. The aim was to correlate protein concentrations of S100A9 in pretreatment serum samples with response to the tumour-necrosis factor (TNF) inhibitor drugs etanercept in a large UK replication cohort. Methods. Pretreatment serum samples from patients with RA (n = 236) about to commence treatment with etanercept had S100A9 serum concentration measured using an ELISA. Following the experimental procedure, S100A9 concentrations were analysed with respect to EULAR response. Results. No evidence of association between S100A9 concentration and EULAR response to the TNFinhibitor biologic drug etanercept was observed following multinomial logistic regression analysis (nonresponder vs moderate responder, P = 0.957; and non-responder vs good responder, P = 0.316). Furthermore, no significant associations were observed when correlating pretreatment S100A9 concentrations with clinical parameters of disease activity (P&gt; 0.05). Conclusion. In the largest replication cohort conducted to date, no evidence for association was observed to support the use of S100A9 as a clinical biomarker predictive of response to the TNF-inhibitor biologic drug etanercept

Newcastle University E-Prints

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort

https://eprint.ncl.ac.uk/fulltext.aspx?url=239627/2238A91B-A531-4DC2-A455-34967722E8EE.pdf&pub_id=239627

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints